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DOI 10.1016/j.ccr.2010.12.023SUMMARYEmbryonal rhabdomyosarcoma (eRMS) shows themostmyodifferentiation among sarcomas, yet the precise
cell of origin remains undefined. Using Ptch1, p53 and/or Rb1 conditional mouse models and controlling
prenatal or postnatal myogenic cell of origin, we demonstrate that eRMS and undifferentiated pleomorphic
sarcoma (UPS) lie in a continuum, with satellite cells predisposed to giving rise to UPS. Conversely, p53 loss
inmaturingmyoblasts gives rise to eRMS, which have the highest myodifferentiation potential. Regardless of
origin, Rb1 loss modifies tumor phenotype to mimic UPS. In human sarcomas that lack pathognomic
chromosomal translocations, p53 loss of function is prevalent, whereas Shh or Rb1 alterations likely act
primarily asmodifiers. Thus, sarcomaphenotype is strongly influenced by cell of origin andmutational profile.INTRODUCTION
Rhabdomyosarcoma is a soft tissue sarcoma showingmyogenic
differentiation. The most common form of rhabdomyosarcomaSignificance
Histology-directed risk stratification is the basis for treating rh
logical phenotypes exist for the embryonal subtype of this tum
of undifferentiated pleomorphic sarcoma by an incremental inc
that embryonal rhabdomyosarcoma (eRMS) and some undiffer
often with similar mutational profiles, but generally arising from
satellite cell phenotype, these tumors are most likely to aris
a subset of p53-deficient eRMSs arising fromMyf6-expressing
odifferentiation approaches.
Cis the embryonal subtype (eRMS) (Breneman et al., 2003).
Metastatic eRMS portends only 40% overall survival
(Breneman et al., 2003). Studies of mouse and man implicate a
number of causative mutations in eRMS that include p53,abdomyosarcoma in children, yet a spectrum of histopatho-
or, some of which can only be discerned from a broad family
rease inmyogenicmarker expression. Here, we demonstrate
entiated pleomorphic sarcomas are a continuum of disease,
different cell(s) of origin. Despite eRMSs having an activated
e from differentiating myoblasts. Importantly, we highlight
myoblasts that aremost likely to respond to therapeutic my-
ancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc. 177
Cancer Cell
Cell Origin and Genetics Modify Sarcoma PhenotypeShh/Ptch1/Sufu, Ras, and Rb1 (Kohashi et al., 2008; Langenau
et al., 2007; Li and Fraumeni, 1969). Numerous descriptive and
animal model studies have given preliminary insight into cell of
origin of eRMS, which is postulated to be the muscle stem cell
(satellite cell) (Hettmer and Wagers, 2010; Tiffin et al., 2003).
However, the cell of origin is debatable because eRMSs not
only express markers of satellite cells (e.g., Pax7; Tiffin et al.
[2003]) but also markers of myoblasts (MyoD, Myogenin) and
differentiated muscle (Desmin, muscle-specific actin) (Morotti
et al., 2006).
Undifferentiated pleomorphic sarcomas (UPSs), synonymous
with either malignant fibrous histiocytoma (MFH) or undifferenti-
ated spindle cell sarcoma (USCS), is a term that is used for the
classification of neoplasms that are presumed to be sarcomas
yet show no definable line of differentiation by histological,
immunohistochemical, ultrastructural, or molecular criteria
(Weiss and John, 2007). The field has been presumed that
many UPSs/MFHs/USCSs are poorly differentiated variants of
well-known sarcomas, which in their more differentiated forms,
would show a defined line of differentiation, as defined by
consistent histological, immunohistochemical, ultrastructural,
or molecular features (Fletcher et al., 2002). However, this asser-
tion is impossible to prove because classification requires char-
acteristics that are dependent on differentiation. It is not unusual
to see undifferentiated sarcomas arising from more differenti-
ated sarcomas that, without the differentiated component being
present, wouldmerit the classification of UPS. Furthermore, UPS
is not a distinct morphological entity. Extensive heterogeneity
exists in the appearance of lesions classified as UPS, ranging
from cellular spindle cell neoplasms to very pleomorphic
neoplasms with epithelioid cytomorphology, suggesting that
UPS may arise from a variety of precursors. Anaplasia, charac-
terized by the presence of tumor cells with large, hyperchromatic
nuclei with or without large atypical mitotic figures, may be seen
in both embryonal and alveolar rhabdomyosarcoma, implying
that diffusely pleomorphic variants without obvious rhabdomyo-
blastic differentiation might exist and that these variants would
be virtually impossible to classify correctly (Qualman et al.,
2008).
In this study we present a genetic dissection of cell of origin
and mutational profile of a series of eRMS models and human
tumors, with specific attention given to the p53, Shh/Ptch, and
Rb1 pathways.
RESULTS
eRMSCanArise fromMuscle StemCells or Downstream
Myogenic Precursor Lineages, but Mutation Profile
Alters Proportions of UPS and eRMS
To generate mouse models of eRMS, lineage-specific homozy-
gous deletion of p53 with or without concurrent heterozygous
Patched1 (Ptch1) deletion was achieved by interbreeding
Ptch1 or p53 conditional lines with the myogenic Cre mouse
lines Mcre (Brown et al., 2005), Myf5Cre (Haldar et al., 2008),
Pax7CreER (Nishijo et al., 2009), or Myf6Cre (Keller et al.,
2004). A diagram correlating Cre-driver expression with stage
of prenatal or postnatal myogenesis is given in Figure 1A.
MCre is specific for the prenatal and postnatal hypaxial lineage
of Pax3 that includes postnatal satellite cells (Brown et al., 2005;178 Cancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc.Relaix et al., 2006). Myf5Cre is specific for the prenatal and
postnatal lineage of Myf5 that includes quiescent and activated
satellite cells and early myoblasts (Beauchamp et al., 2000;
Cornelison and Wold, 1997; Kuang et al., 2007), as well as
mesenchymal precursors of brown fat (Seale et al., 2008).
Pax7CreER is specific for the postnatal lineage of Pax7 that
includes quiescent and activated satellite cells (Nishijo et al.,
2009), and Myf6Cre is specific for the prenatal and postnatal
lineage of Myf6 that includes maturing myoblasts (Keller et al.,
2004). For activation of Pax7CreER, tamoxifen was adminis-
tered intraperitoneally 4 weeks after birth for 5 consecutive
days, as previously described (Nishijo et al., 2009). Results of
conditional mouse crosses are shown in Figure 1B. When p53
was homozygously inactivated, tumors arising in the different
mouse Cre lines developed at a penetrance rate of 13%–56%
within a 600-day follow-up period. Myf5Cre-p53/ or Myf5-
Cre-Ptch1+/;p53/ developed tumors at the highest
frequency (60% at 500 days, Figures 1C and 1D). Tumors
among most of these mouse lines distributed to the extremities,
trunk, and face, except that tumors did not occur on the face of
Myf6Cre mice. A strong propensity for regional lymph node
metastasis and distant metastases to the lungs was seen in
all of these mouse lines (greater than two-thirds of mice that
developed tumors).
Histological assessments were made by a pathologist
(B.P.R.) specialized in pediatric and adult sarcoma pathology.
The histological appearance of eRMS varied from tumors
composed of spindle cells without obvious rhabdomyoblastic
differentiation to neoplasms composed of an admixture of prim-
itive appearing to spindle shaped cells with variable numbers of
epithelioid or spindle cell-shaped rhabdomyoblasts. Occasional
cases of eRMS exhibited cross striations. Invariably, all cases
of eRMS expressed Desmin and Myogenin or MyoD. UPS
varied in histological appearance but did not contain cells
with the histological appearance of rhabdomyoblasts and
generally lacked unequivocal strong and/or widespread Des-
min, Myogenin, and MyoD expression by immunohistochem-
istry. Cases for which the diagnosis was indeterminate between
UPS and eRMS with possible focal rhabdomyosarcomatous
differentiation were reviewed by two other sarcoma patholo-
gists (Z.Y. and D.M.P.). For mice harboring only Cre-driven
p53 deletions, tumors were soft tissue sarcomas except that
half of Myf5Cre-p53 tumors were osteosarcoma arising from
the ribs (Figure 1E). Occurrence of osteosarcoma in Myf5Cre-
p53 mice is consistent with a previous report that embryonic
Myf5 lineage contributes to rib morphogenesis (Haldar et al.,
2008). Ptch1+/;p53/ mice of all Cre lineages had a tendency
to develop tumors at a higher frequency than did p53/ mice,
although this trend did not reach statistical significance (Fig-
ure 1B). All Ptch1+/;p53/ tumors were soft tissue tumors
except for osteosarcoma. Osteosarcoma rarely arose from
Myf5Cre-Ptch1+/-;p53/ mice (<10%), whereas it occurred
in a larger proportion of Myf5Cre-p53/ mice (Figure 1E).
Histological diagnosis of the soft tissue tumors included a spec-
trum of myogenic malignancies, ranging from alveolar and
embryonal RMS to UPS. eRMS arose from all Cre-driver
mice, suggesting that eRMS could occur in a range of
myogenic lineages. Myf6Cre-p53/ gave rise to the highest
percentage of eRMS (100%) in the context of p53 deletion
Figure 1. Survival Analysis and Tumor Histology of Each Genotype
(A) Representation of prenatal and postnatal myogenesis in the context of Cre drivers used to activate tumorigenesis in this study. multi-nucl., multinucleated.
(B) Disease-free survival is shown as a Kaplan-Meier curve for conditionally homozygous p53-deleted mice with or without conditional Ptch1 haploinsufficiency,
using different Cre alleles.
(C and D) Comparison of disease-free survival in different Cre mice when p53 alleles were conditionally, homozygously deleted (C), or when p53 alleles were
conditionally, homozygously deleted concurrently with heterozygous conditional Ptch1 deletion (D). The difference between p53 and Ptch1-p53 disease-free
survival did not reach statistical significance by the log rank test (p > 0.05).
(E) Histological classification. Mean latency of eRMS (red slices) is shown below each pie chart.
See also Figure S1 and Tables S1–S3.
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Cell Origin and Genetics Modify Sarcoma Phenotypeonly (Figure 1E), and MCre was the second highest with 31%
and 42% of the tumors diagnosed as eRMS in p53/ and
Ptch1+/;p53/, respectively (Figure 1E). eRMS developed in
13% of Pax7CreER-Ptch1+/;p53/ mice but in none of theCPax7CreER-p53/ mice, most tumors of which were diag-
nosed as UPS (Figure 1E). These data suggest that PAX7+
satellite cells can give rise to eRMS, but their degree of
myogenic differentiation is lower than tumors that arise fromancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc. 179
Figure 2. Histological Analysis of Ptch1+/–;p53–/– eRMS for Each Cre Line
Genotypes are indicated in column headings. A tumor from a mouse with germline deletion of the Ptch1 gene is shown as a typical case of eRMS (left column).
H&E staining, Masson’s trichrome, and immunohistochemical staining for Myogenin and Desmin were performed for diagnosis of all tumors. Arrowheads point to
eosinophilic strap-like epithelioid rhabdomyoblasts in H&E panels. Cross striations are shown on trichrome (some cases; arrowheads). Scale bar, 40 mm.
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Cell Origin and Genetics Modify Sarcoma Phenotypematuring myoblasts (the Myf6 lineage). Representative cases
with eRMS histology are shown in Figures 2 and 3. These
murine eRMS cases were also found to express markers
commonly associated with human eRMS (Davicioni et al.,
2006; Grass et al., 2009) that also allowed murine eRMS and
murine aRMS to be distinguished by linear discriminate analysis
(see Figures S1A–S1C available online).
Cell of Origin Cannot Be Inferred from Tumor Phenotype
To examine whether tumors from a specific lineage continue to
express the original myogenic markers when Cre recombinase
was triggered, expression of Myf5, Pax7, Myf6, and Pax3 was
studied by quantitative RT-PCR (Figure S1D). None of these
genes was upregulated in the tumors from the original lineage
compared to other groups of tumors (e.g., Myf6 is not
overexpressed in soft tissue tumors from Myf6Cre-Ptch1+/-
;p53/ or Myf6Cre-p53/ mice compared to tumors of other
mouse lines). Unsupervised global gene expression analysis
also failed to demonstrate a relationship between cell of origin
and molecular phenotype for fusion-negative (non-aRMS)
sarcomas (Figure S1E). Results of pattern recognition analysis
were similar (Table S1 shows high classification errors).
These findings suggest that expression of myogenic markers180 Cancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc.inherent to the myogenic lineage that gave rise to tumors may
not be retained after tumorigenic transformation. Therefore,
expression of these markers does not reflect the cell of origin
in rhabdomyosarcoma.
Rb1 Absence Is a Modifier, Leading to Loss
of Differentiation of Sarcomas
High frequency of retinoblastoma (Rb1) gene mutation has been
reported in a subset of human rhabdomyosarcoma (Kohashi
et al., 2008). To examine the effect of Rb1 loss on eRMS devel-
opment, we inactivated both p53 and Rb1, with or without Ptch1
haploinsufficiency. Loss ofRb1 in theMyf5 or hypaxial Pax3 line-
ages (Myf5Cre and MCre, respectively) led to embryonic
lethality, which is consistent with a previous report (Huh et al.,
2004). When Rb1 was inactivated in Myf6 or Pax7 lineage using
Myf6Cre or Pax7CreER mice, mice were born in normal Mende-
lian ratios and developed normally throughout adolescence and
early adulthood. Unexpectedly, most of these mice developed
silent pituitary corticotropinomas instead of rhabdomyosarcoma
(Hosoyama et al., 2010), and less than 10% of these mice devel-
oped soft tissue tumors (data not shown). On histological anal-
ysis these rare soft tissue tumors were usually composed of
undifferentiated spindle cells without rhabdomyoblasts or other
Figure 3. Histological Analysis of p53–/– eRMS in Each Cre Line
Representative caseswith eRMSare presented. H&E staining, Masson’s trichrome, and immunohistochemical staining of Myogenin and Desmin were performed
for diagnosis of all tumors. Eosinophilic rhabdomyoblasts are highlighted by arrows. Scale bar, 40 mm.
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criteria for eRMS or aRMS with Desmin and Myogenin or
MyoD immunoreactivity. Two bona fide cases of eRMS from
this cohort are shown in Figure 4. Myogenin and Desmin-posi-
tive tumor cells were far less frequent than Ptch1+/;p53/ or
p53/ tumors with intact Rb1 (from any Cre driver). The most
strongly staining tumors are shown in Figure 4 to emphasize
that, in a subset of these UPS tumors, focal Myogenin and
Desmin staining was sometimes present. Overall, these results
suggest that Rb1 loss may lead to loss of differentiation in
sarcomas. Unsupervised global gene expression analysis
demonstrated a strong difference between tumors with intact
versus deleted Rb1 (Figure S1F). Pattern recognition analysis
similarly showed that the ability to discriminate between
fusion-positive aRMS and fusion-negative soft tissue sarcomas
was diminished when Rb1 was homozygously deleted
(Table S2).
Tumors of theMyf6 Lineage Show the Highest Degree
of In Vitro Myodifferentiation, which Is Negated
by Rb1 Loss
To examine the myogenic differentiation potential of tumors
from different lineages, an in vitro differentiation assay was per-
formed using primary tumor cell cultures (Figure 5). Tumor
cells from Myf6Cre-p53/, Pax7CreER-p53/, Myf6Cre-
Ptch1+/;p53/,Pax7CreER-Ptch1+/;p53/,Myf6Cre-p53/;
Rb1/, Pax7CreER-p53/;Rb1/, and Myf6Cre-Pax3P3F/P3F;Cp53/mice were cultured under myogenic differentiation condi-
tion for 5 days. Immunofluorescent stainingofmyosin heavy chain
(MHC) shows that the number ofMHC-positive cells was higher in
Myf6Cre-p53/ cells than in Pax7CreER-p53/ cells
(15% versus 2%, Figures 5A and 5B). Fusion index defined as
MHC-positive multinucleated cells was also higher in Myf6Cre-
p53/ cells than inPax7CreER-p53/ cells (Figure 5C). Concur-
rent Rb1 and p53 inactivation decreased MHC-positive cells and
the fusion index in Pax7CreER-p53/ cells (Figures 5B and 5C),
supporting our previous observation that Rb1 loss may lead to
an undifferentiated phenotype (Figure 4). To examine the relation-
ships between growth ability and myodifferentiation, eRMS cells
were stained for the S-phase marker Ki67. Myf6Cre-p53/ and
Pax7CreER-p53/ cells showed similar percentages of Ki67
positivity (Figure 5D). On the other hand,Myf6Cre-p53/;Rb1/
and Pax7CreER-p53/;Rb1/ tumor cells also showed Ki67
positivity similar to each other but significantly higher than tumors
with intact Rb1. The difference in cell growth rates between
tumors with and without Rb1 deletion was accentuated under
low-serum conditions (Figures 5E and 5F). These results suggest
that cell of origin does not affect cell proliferation; however, the
difference in myogenic differentiation between Myf6Cre and
Pax7CreER tumors may be linked to the degree of myogenic
differentiation of the cell from which these tumors are derived
rather than alterations in growth ability. The results also suggest
that loss of Rb1 can increase tumor cell proliferation and reduce
myogenic differentiation.ancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc. 181
Figure 4. Histology of Ptch1+/–;p53–/–;Rb1–/– eRMS
from Pax7CreER and Myf6Cre Lines
Shown are the areas with the most immunoreactivity. The
majority of the tumors did not exhibit immunopositivity.
Histologically, tumors appeared as either poorly differenti-
ated epithelioid cell (left) or spindle cell (right) neoplasms
and only showed rhabdomyoblastic differentiation by
immunohistochemistry. Scale bar, 40 mm. See also Fig-
ure S2.
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Cell Origin and Genetics Modify Sarcoma PhenotypeAn additional interesting result was that all eRMS primary cell
cultures showed a greater capacity for terminal myogenic
differentiation than Myf6Cre-Pax3P3F/ P3F; p53/ aRMS
primary cell cultures. This result is consistent with reports of
human patients treated with multimodal therapies (chemo-
therapy, radiation), whereby eRMS tumors show features of
myodifferentiation in association with treatment effect, but
aRMS tumors fail to undergo cytodifferentiation after therapy
(Smith et al., 2002).eRMS and UPS Are Part of a Tumor Continuum
Having compared the myodifferentiation capacity of eRMS by
cell of origin relative to aRMS, we next explored in more detail
the observation that Pax7CreER-Ptch1+/;p53/ tumors were
often morphologically similar but showed varying degrees of
phenotypic differentiation leading to the pathological diagnosis
of either eRMS or UPS. To this end we examined markers of
myodifferentiation among Ptch1+/;p53/ or p53/ mouse
tumors from any cell of origin, correlating cohorts of tumors
diagnosed by the pathologists as eRMS or USCS (i.e., UPS),
based upon histological features with Myogenin or Desmin
staining. UPS tumors expressed significantly lower levels of
satellite cell, myoblast, and myofiber marker genes Pax7,
Myf6, and Ckm (muscle creatine kinase) than eRMS, although182 Cancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc.murine aRMS and murine UPS were not statis-
tically different for these genes. Among human
pediatric fusion-negative soft tissue sarcomas,
a decreasing gradient was again seen for
these markers in eRMS, eRMS spindle cell
variant, non-eRMS spindle cell RMS, and
UPS, respectively (Figure 6A). Thus, eRMS
and UPS appear to lie in a continuum of
myodifferentiation.
To further characterize the gene expression
profile specific to tumors histologically diag-
nosed as eRMS, we performedmicroarray anal-
ysis for histologically confirmed murine eRMS,
murine UPS (non-eRMS), and skeletal muscle
of 4-week-old (juvenile) mice. Expression of
select genes was validated by quantitative RT-
PCR. Supervised clustering of microarray data
identified two gene clusters whose increased
expression was associated with eRMS and
non-ERMS, respectively (Figure 6B; Table S3).
Supervised clustering that differentiated tumors
with and without rhabdomyoblasts showed
a pattern similar to clustering of eRMS versusnon-eRMS, respectively (data not shown). A third gene cluster
was shared between skeletal muscle (SKM) and eRMS. Principal
component analysis of both mouse tumors (Figure 6C) and
human fusion-negative soft tissue sarcomas, including eRMS
(Figure 6D), supports the assertion that eRMS and UPS lie in
a continuum.Five Genes Differentiate Skeletal Muscle, eRMS, UPS,
and aRMS
To determine whether a profile of a limited number of mRNA
levels could be used diagnostically to differentiate human
eRMS, UPS, and aRMS, we used selected RT-PCR validations
of gene expression data from results of microarray studies in Fig-
ure 6B to test possible tumor classification profiles. Using
K-nearest neighbors and Support Vector Machines methods to
identify a reduced number of gene expression classifiers,
a profile of five genes was developed (BMP4, MYF5, DLK1,
PAX7,CAV1) (Figure 7A). Using Leave-One-Out cross validation,
the five gene profiles agreed with Pediatric CHTN pathologist
diagnoses for 12 out of 12 human SKMs, 23 out of 24 eRMSs,
seven out of nine UPSs, and five out of five aRMSs (Table S4).
However, this profile classified seven out of ten spindle cell
variant eRMSs as classical eRMS, and predicted four out of six
spindle cell rhabdomyosarcomas as eRMS. Overall sensitivities
Figure 5. Cellular Phenotypes of Primary Tumor Cell Cultures Vary by Cell of Origin and Mutation Profile
(A) Cell lines from both Myf6Cre-p53 and Pax7CreER-p53 tumors formed multinuclear myotubes, which were positive for MHC. Scale bar, 40 mm.
(B) Percentage of MHC-positive cells was calculated in each cell line. Total cells in five views of 1003 fields were counted in each cell line. WT, wild-type; mut,
mutant; aRMS, alveolar rhabdomyosarcoma tumors from Myf6Cre-Pax3P3F/P3F;p53/ mice.
(C) Fusion index (percentage of cells with MHC-positive [MHC+] multinuclear myotubes/total cells) was calculated.
(D) Ki67 index (percentage of Ki67-positive cells/total cells) was calculated.
(E and F) In vitro growth properties of each cell line under normal (10% fetal bovine serum [FBS], E) and low (1% FBS, F) serum conditions. Vertically oriented
brackets represent comparisons for which p values are <0.001.
For all panels in this figure, p values represent ANOVAwith Tukey’s multiple testing correction. For (B) and (C), values were log transformed. Rank order was used
for (D). Error bars represent SEM.
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Cell Origin and Genetics Modify Sarcoma Phenotypefor these tumor types were 78%–100%, and specificities were
71%–98% (Table S5).
eRMSs Have a Unique Phenotype Resembling
an Activated Satellite Cell Program
Results of the preceding microarray analysis, RT-PCR valida-
tions, and classification schemas not only reflected that
eRMS expressed genes associated with myogenesis as well
as previously reported RMS-related genes but that eRMS
harbored an activated satellite cell program. In general, genesCwhose increased expression was associated specifically with
eRMS include Secretin (Sct) (Figure 7B), a gastrointestinal
peptide expressed in the inner circular intestinal wall muscle
of the developing mouse fetus (Siu et al., 2005), and the gamma
(fetal) nicotinic cholinergic receptor (Chrng) (Figure 7B), which
was previously reported to be expressed in a high percentage
of eRMSs and aRMSs (Gattenloehner et al., 1999). Other
eRMS-specific genes include embryonic myosin heavy and
light chains (Myh3 and Myl4, respectively; Figure 7B), which
are in keeping with an embryonic muscle developmentancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc. 183
Figure 6. Continuum of Gene Expression Features in Mouse and Human Sarcomas
(A) Expression of myogenic markers in mouse and human SKMs, eRMSs, UPSs, and intermediate diagnoses. aRMS is shown in comparison. Mouse genes have
the first letter capitalized, whereas human genes have all letters capitalized. Error bars represent SEM.
(B) Supervised clustering identified the genes specifically upregulated in each group, eRMS, non-eRMS (UPS), and skeletal muscles (SKM) (raw p value <0.05 and
fold change >2). A gene list of eRMS-specific genes is shown as Table S2. Tumors analyzed are Ptch1,p53 tumors without Rb1 deletions from Pax7CreER,MCre,
Myf5Cre, and Myf6Cre lineages.
(C) Principal component analysis for mouse tumors using the 345 signature genes that differentiated ERMS (red) and UPS (blue) mouse tumors from normal skel-
etal muscle (black).
(D) Principal component analysis for human RMS, UPS, and normal skeletal muscle samples using 283 significant probes that reached significance (p value <0.05
and fold change >1.5).
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shared between eRMS and activated satellite cells (Fukada
et al., 2007). These shared genes include Pax7 (Figure 6A),
Sct, Myh3, Chrng, cardiac troponin T2 (Tnnt2), hairy and
enhancer of split 6 (Hes6) (Figure 7B), RIKEN cDNA
1110002H13 gene, Otogelin (Otog), low density lipoprotein184 Cancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc.receptor-related protein 4 (Lrp4), guanine nucleotide binding
protein alpha inhibiting 1 (Gnai1), unc-5 homolog B (Unc5) (Fig-
ure S2), MyoD, distal-less homeobox 2 (Dlx2), and Rho GDP
dissociation inhibitor gamma (Arhgdig). Overall, eRMS-specific
gene expression shows great similarity to activated satellite
cell gene expression.
Figure 7. Gene Expression Classifiers and Phenotypes in Mouse and Human Sarcomas
(A) Expression of genes that as a profile differentiate SKM, eRMS, USCS/UPS. and aRMS in humans, with corresponding graphs from mouse models. Pax7 is
included in this five gene profile, but Pax7 expression data are presented in Figure 6A.
(B) Markers of activated satellite cells found to be highly expressed in mouse and human eRMS. Mouse genes have the first letter capitalized, whereas human
genes have all letters capitalized.
See also Figure S2. Error bars represent SEM. See also Tables S4 and S5.
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Altered p53, Shh/Ptch1, and Rb1 Signatures
To determine the relevance of our mouse sarcoma models to
human disease, we examined the gene expression profiles of
111 primary human fusion-negative rhabdomyosarcomas and
related cell lines for which microarray data sets were available
(Davicioni et al., 2006; Lae et al., 2007).
Individual p53 off, Shh on, Rb1 off, and Ras on signatures are
presented in Figures 8A–8D, Figure S3, and Tables S6–S9.
A global examination is given in Figure 8E. From this limited
cohort of 111 fusion-negative soft tissue sarcoma samples
(mostly diagnosed as eRMS by Children’s Oncology Group
central review or the Triche laboratory), the predominant feature
is p53 loss in 59% of samples. Of that 59%, nearly half exhibited
only the p53 off signature. Both Shh on and Rb1 off signatures
were rare and often concurrent with one or more other signa-
tures. Nineteen percent of tumors exhibited all three signatures.CSurprisingly, a Ras signature was not seen alone in any tumor but
existed together with at least one other signature in 21% of
samples (Figure 8E; Figure S3 and Table S10). Clinical covariates
by signature status are presented in Table S10. Too few samples
were present to draw any conclusion on signature versus
disease stage at diagnosis or survival; however, an interesting
finding is that three of four USCS (i.e., UPS) samples exhibited
an Rb1 off signature. Also of note, 32 of 111 samples (29%) ex-
hibited no p53, Shh, or Rb1 signature.
DISCUSSION
A great deal of research on rhabdomyosarcomas is given to
aRMS, which is associated with especially poor prognosis
when metastatic (<20% long-term survival) (Breneman et al.,
2003), whereas comparatively less attention is given to eRMS,
for which long-term survival when metastatic is still merelyancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc. 185
Figure 8. Heat Maps of Human Fusion-Negative Rhabdomyosarcomas for Gene Signatures Representing the p53, Shh, and Rb1 Pathways
(A) The p53 pathway heat map represented as two metagenes was generated based on 320 significant genes (Benjamini and Hochberg adjusted p value <0.05
and fold change >2). Metagene 1 represents 183 genes, and metagene 2 represents 136 genes. In total, 65 of 111 fusion-negative RMS primary tumor samples
(59%) exhibited a gene expression signature consistent with the ‘‘p53 off’’ state for which the S-score was greater than 0.761 (see Supplemental Experimental
Procedures). All human breast cancer control samples with known p53 mutations also exhibited S-scores greater than 0.761.
(B) For the Shh-signaling pathway heat map, 111 genes were employed, 56 of which were in metagene 1, and the other 55 genes were in metagene 2. Overall, 32
of 111 (29%) of tumors exhibited a gene expression signature consistent with a ‘‘Shh on’’ overdrive state for which S-score was greater than 0.444. The p value for
comparison of the S-score for Shh+medulloblastoma controls and for Shhmedulloblastoma controls was 2.623 105, as calculated by theWilcoxon rank sum
test.
(C) For the Rb1 pathway, 381 genes were used to construct the heat map, with 157 in metagene 1, and 224 genes in metagene 2. For the Rb1 pathway, 42 of 111
(38%) of samples demonstrated an ‘‘Rb1 off state’’ with an S-score greater than 0.345.
(D) To evaluate the Ras pathway, 87 genes common to zebrafish eRMS and human Ras-driven pancreatic cancer were used to construct the heat map, with 24
genes inmetagene 1, and 63 genes inmetagene 2. For the Ras pathway, 25 of 111 of samples demonstrated a ‘‘Ras on’’ state with an S-score greater than 0.477,
but after exclusion of two samples that did not also contain a Ras signature common to Ras-activated mammary epithelial cells, only 23 of 111 samples (21%)
were felt to have a strict Ras signature. None of the Ras signature samples (breast similar or pancreatic similar) had a Ras-activation signature in the absence of
mutant p53, Shh, or Rb1 signatures.
(E) Venn diagram showing the intersection of signatures among human fusion-negative soft tissue sarcomas. ca, cancer. Ras On samples are encircled with
dotted lines.
See also Figure S3 and Tables S6–S10.
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given to UPS, although a few promising studies are emerging
(Nakayama et al., 2007). In the current study we have examined
several key aspects of eRMS and UPS biology. We have demon-
strated that eRMS, spindle cell rhabdomyosarcoma, and UPS lie
in a continuum. Interestingly, the spindle cell subtype of eRMS
was originally identified as a well-differentiated subtype that
occurred predominantly in children and had a favorable prog-
nosis (Leuschner et al., 1993). However, subsequent studies
have shown that spindle cell rhabdomyosarcomas can be very
aggressive, especially in adults. The murine spindle cell rhabdo-
myosarcomas identified in our study appear most akin to spindle
cell rhabdomyosarcomas in adults. Although rhabdomyosar-
coma can arise from various stages of myogenic differentiation
ranging from satellite cells to maturing myoblasts, the proportion
of rhabdomyosarcomas versus USCSs (i.e., UPS) varies both by
cell/lineage of origin and mutational spectrum. We have shown
that p53 and/or Ptch1 mouse models give rise to histologically
and immunohistochemically authentic eRMS tumors with the
same molecular expression profile as human eRMS, whereas
Rb1 loss reduces the myodifferentiation potential of these tumor
models and increases proliferative capacity to the level seen in
aRMS. By global gene expression analysis, we uncoupled the
gene expression signature for eRMS from that of UPS in the
mouse, demonstrating that the former is consistent with an
activated satellite cell phenotype. By examining human Pax:Fkhr
fusion-negative rhabdomyosarcomas, we have established that
p53 loss-of-function, Shh gain-of-function, and Rb1 loss-of-
function gene expression signatures are highly prevalent in
human primary eRMS tumors and often are present concur-
rently. Thus, our mouse models are pertinent to specific subsets
of human fusion-negative soft tissue sarcomas.
A Continuum Exists between eRMS and UPS
Features of myogenic differentiation distinguish eRMS from
other forms of sarcoma, although common disagreement about
classification may be basedmore in biology than previously real-
ized. Historical discordance rates between institutional and
centralized Intergroup Rhabdomyosarcoma Study Group
(IRSG) diagnoses of eRMS NOS, spindle cell eRMS, and undif-
ferentiated sarcoma have been reported at 19%, 97%, and
37%, respectively (Qualman et al., 1998), although the diagnosis
of undifferentiated sarcoma has become much more refined
than in this past era due to the ability to identify even focal differ-
entiation by improved immunostains. The relatedness of this
family of sarcomas is also reflected in the fact that eRMS and
Pax:Fkhr fusion-negative aRMS are difficult to discern from
one another using gene expression and comparative genomic
hybridization tools (Davicioni et al., 2009; Wexler and Ladanyi,
2010;Williamson et al., 2010). Conversely, ultrastructural studies
of UPS suggest features in common with myofibroblastic differ-
entiation (Suh et al., 2000). The experimental results of our
current study suggest that at least a subset of UPSs and eRMSs
may share a common myogenic cell (or cells) of origin but that
UPSs are more likely to evolve from Pax7-expressing satellite
cells (muscle stem cells). From this common muscle stem cell
of origin, divergence of maturation possibly accounts for the
continuum of tumor cell phenotypes that was observed in this
study. Recognizing the continuum fromUPS to eRMS, onemightCprospectively be able to use the molecular signatures for UPS
and eRMS obtained from this study to enhance the classification
and to improve the ability to predict prognosis and response to
molecularly targeted therapies. Our first attempt at this effort
generated a five gene expression profile (BMP4, MYF5, DLK1,
PAX7, CAV1) that correctly classified human eRMS versus
UPS versus aRMS with high sensitivity and good specificity;
however, to prove this profile’s clinical value, prospective valida-
tion studies must be performed.
Rhabdomyosarcomas Can Arise from Myogenic
Precursors, but Not a Single Cell Type or Lineage
of Origin
An important question in the field is, ‘‘What is the cell of origin of
rhabdomyosarcoma?’’ (Hettmer and Wagers, 2010). Epidemi-
ology indicates that the incidence of eRMS increases from
toddler (classical eRMS) to adolescent ages (spindle cell variant)
(Ognjanovic et al., 2009; Pastore et al., 2006), periods when
muscle growth accelerates and satellite cell activity may be high-
est. By contrast, aRMS incidence does not vary by age or sex
(Ognjanovic et al., 2009; Pastore et al., 2006).
It is reasonable to expect that rhabdomyosarcoma tumor cell
phenotypes might imply cell of origin. Indeed, some have
suggested that human eRMSs arise from satellite cells because
these tumors express the satellite cell marker Pax7 (Tiffin et al.,
2003). Based upon expression patterns in mouse tumors, other
investigators have similarly postulated a (neural crest) cell of
origin for double mutant NF1 and p53-associated rhabdomyo-
sarcoma (Vogel et al., 1999). However, a satellite cell phenotype
for some forms of rhabdomyosarcomas is supported experi-
mentally for tumor models driven by the Ras pathway (Langenau
et al., 2007).
Further evidence that eRMS may arise from satellite cells is
supported by the observation that 40% of eRMSs arise in the
orbit (Gurney et al., 1999) and that cranial muscle, including
the orbit, has a higher density of satellite cells than most noncra-
nial hypaxial or epaxial muscle tissue (McLoon et al., 2004).
Interestingly, the extraocular muscles have a very high density
of muscle stem cells (satellite cells) that are continuously under-
going proliferation and renewal (McLoon et al., 2004) and are
known to be more resilient and less prone to the effects of
muscle dystrophy than noncranial muscles (Porter et al., 2003).
Head and neck tumors, but not orbital ones, exhibit the bimodal
increased age incidences described above, probably because of
the increase in spindle cell variant eRMS during adolescence
(Pastore et al., 2006). Genitourinary sites exhibit a strong age
distribution in 0- to 3-year-old children, which is puzzling at first
because these sites are generally not associatedwith either skel-
etal muscle or satellite cells. However, revealing contemporary
reports of the presence of satellite cells in the urethral rhabdos-
phincter are emerging (Sumino et al., 2007), and the presence of
similar cells in other regions of the bladder, the prostate, and
biliary tract is intriguing.
Our results show that Pax7-expressing murine satellite cells
indeed can be the cell of origin of eRMS, although more differen-
tiated, Myf6-expressing myoblasts are also capable of forming
eRMS with approximately the same latency. Given the clinical
presentations of rhabdomyosarcoma arising from satellite cell-
rich muscles at corresponding age periods of muscle growth,ancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc. 187
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humans—but maybe not the major (or only) cell of origin. Indeed,
other cells of origin may not (initially) be myogenic at all. In an
example inferred for alveolar rhabdomyosarcoma, Lagha et al.
(2009) reported that in the mouse embryonic dermamyotome,
the ratio of Pax3 to Foxc2 balances fate between myogenic
and vascular cell fates but that Pax3:Fkhr suppresses Foxc2.
This latter result suggests that, in the susceptible cell, an angio-
genic precursor might be converted to a myogenic state, a result
that has been shown experimentally for embryonic aortic meso-
angioblasts (Messina et al., 2009). Therefore, our demonstration
of susceptibility of myogenic precursors to embryonal rhabdo-
myosarcomagenesis may be only the beginning of a very inter-
esting biological story about the plasticity of different cell
lineages.
Mutational Profile Determines Tumor Phenotype
Many pathways lead to eRMS, but themost well-known pathway
is the germline disruption of p53 in Li-Fraumeni syndrome (LFS).
Originally described as familial RMS (Li and Fraumeni, 1969),
LFS is commonly associated with eRMS, although histologically
diagnosed alveolar rhabdomyosarcoma (for which Pax:Fkhr
fusion status is often unknown) can also occur in LFS (Diller
et al., 1995). Our mouse model studies suggest that p53 loss
can give rise to pure eRMS if derived from a Myf6-expressing
maturing myoblast cell of origin, but not from a satellite cell of
origin. However, our studies of human tumors suggest that
a p53 loss-of-function signature is extremely prevalent in
fusion-negative sarcomas and eRMS (as much as 59% of
tumors). One of the potentially most clinically relevant findings
from our mouse model studies is that mouse tumors with
a p53 off signature only and a Myf6 lineage origin may have
the highest potential for ‘‘differentiation’’ therapy using agents
other than chemotherapy or radiation. Prospective mutational
profiling and ex vivo myodifferentiation assays may identify
patients who are candidates for this approach. An important
caveat is that Myf6 expression itself would not be appropriate
for identifying tumors derived from a Myf6-expressing cell of
origin because, as we show fromour RT-PCR assays (Figure S2),
tumor phenotype does not reflect cell of origin.
A role for the Shh/Ptch1-signaling pathway in eRMS is impli-
cated by the association of human congenital Ptch1 haploinsuf-
ficiency with the occurrence of cardiac rhabdomyoma and
eRMS (Beddis et al., 1983; Gorlin, 1987; Tostar et al., 2006).
Additional supporting evidence for Shh playing a role in a subset
of eRMSs is provided by observational studies using human
tumors wherein expression of the Shh-signaling cascade is
altered (Oue et al., 2010; Tostar et al., 2006). The initial experi-
mental demonstration of Ptch1 haploinsufficiency being linked
to eRMS tumor initiation was reported by Hahn et al. (1998).
A persistent role for Shh overdrive in tumor progression of
Ptch1 haploinsufficient mice is suggested by Ptch1 reporter
expression in murine rhabdomyosarcoma (Gerber et al., 2007).
The results of our paper further indicate that Ptch1 haploinsuffi-
ciency can contribute to tumor initiation from myogenic cells of
origin at every level of differentiation, which is not the case
when p53 alone is lost in Pax7-expressing satellite cells or
Myf5-expressing myoblasts. In our analysis of human fusion-
negative sarcomas and eRMS, evidence of Shh overdrive was188 Cancer Cell 19, 177–191, February 15, 2011 ª2011 Elsevier Inc.present in 29% of tumors but almost always in association
with p53 or Rb1 gene signatures. Thus, Ptch1 does play an
important role in tumor initiation and neoplastic myogenesis;
however, in sporadic tumors Ptch1 does not often appear to
act in isolation. For this reason the Pax7CreER-Ptch1-p53
mouse model may be a very good preclinical tool for studying
the spindle cell variant of eRMS.
Although Ras has been implicated in pediatric eRMS (Chen
et al., 2006; Martinelli et al., 2009; Stratton et al., 1989), the
surprising result that an activated Ras signature was only
present in combination with other mutant signatures is consis-
tent with the demonstrated role of Ras at initiation of adult pleo-
morphic rhabdomyosarcoma (Doyle et al., 2010; Tsumura et al.,
2006) but suggests that Ras may only be a modifier in pediatric
eRMS. We were struck by the contrast between the 10% of
human tumors that expressed all four mutant signatures versus
the 28% tumors that only coveted a p53 off signature. Therein
may exist an opportunity for molecular stratification (and inter-
vention) in eRMS.
Perhaps the most interesting observation is that we could not
identify a signature for 29% of human fusion-negative soft tissue
sarcoma, underlining the possibility that mutations independent
of p53 have yet to be discovered and modeled.
Rb1 Is a Modifier in eRMS
Early studies suggested that Rb1 abnormalities rarely occur in
eRMS or aRMS (De Chiara et al., 1993), but a recent study
reports that Rb1 allelic imbalance occurred in 13 of 27 eRMSs
tested (but much less frequently than in aRMS) (Kohashi et al.,
2008). In a second contemporary series, six of 36 eRMSs lacked
pRb1 staining on IHC (Takahashi et al., 2004). Other supporting
evidence for pRb family proteins being implicated in eRMS
comes from the observation of SV40 Tag expression from
a LFS eRMS (Malkin et al., 2001). However, among patients
with hereditary Rb1 mutations, rhabdomyosarcomas reported
to have occurred were more often categorized as RMS ‘‘Not
Otherwise Specified (NOS)’’ than eRMS (note that NOS may
imply inadequate tissue rather than diagnostic uncertainty)
(Kleinerman et al., 2007). Our studies in mouse models suggest
that although Rb1 loss of function alone does not lead to tumor
initiation, Rb1 loss of function in combination with other onco-
genic factors is strongly associated with an undifferentiated
phenotype, wherein myogenic marker expression is reduced or
absent. Tumor cell proliferation (Ki67 positivity) andmyodifferen-
tiation capacity under low-serum conditions were also severely
altered. Therefore, Rb1 is best characterized as a ‘‘modifier’’ of
phenotype in eRMS.
eRMSs Share Features of Activated Satellite Cells
Perhaps the most fascinating aspect of this study is the high
concordance of gene expression between murine eRMS and
murine-activated satellite cells—regardless of whether cell of
origin is a satellite cell or a maturing myoblast. The data suggest
that eRMS may represent a myogenic precursor state (as
opposed to an opportunistic expression of early myogenic
markers) and that treatment might be guided by this principle.
Past clinical studies indirectly support this assertion, that in
eRMS (but not aRMS) myodifferentiation of tumor cells corre-
lates with response to treatment (Smith et al., 2002), and
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relapse even if present many years (Arndt et al., 2006). Thus,
we speculate that specific subsets of eRMSs that are phenotyp-
ically similar to activated satellite cells are poised for
differentiation.
EXPERIMENTAL PROCEDURES
Mice
All animal procedures were conducted in accordance with the Guidelines for
the Care andUse of Laboratory Animals andwere approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Texas Health
Science Center at San Antonio. Detailed descriptions of mouse lines and
repository status are given in Supplemental Experimental Procedures.
Human Tissue Samples
De-identified human samples were obtained with approval from the UTHSCSA
institutional review board via the Pediatric Cooperative Human Tissue
Network, Columbus, OH. Fusion status of aRMS samples was performed as
previously described (Barr et al., 2006).
Pathology
Methods for histopathological analysis are given in the Supplemental Experi-
mental Procedures. Slides were sequentially reviewed by three pathologists
(B.P.R., Z.Y., and D.M.P.), and concurrencewas reached in all cases regarding
diagnosis of eRMS. Diagnostic criteria of eRMS as well as the procedures for
primary cell cultures are given in Supplemental Experimental Procedures.
Gene Expression Analysis
Mouse gene expressionmicroarray data were generated using IlluminaMouse
Ref-8 BeadChip v1.1 (Illumina, San Diego, CA). Detailed analysis procedures
and methods for RT-PCR validation assays are given in the Supplemental
Experimental Procedures.
ACCESSION NUMBERS
Microarray data sets were deposited in the GEO database as accession code
GSE22520.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and ten tables and can be found with this article online at
doi:10.1016/j.ccr.2010.12.023.
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